Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Xue, Feng; Han, Lu; Ma, Sijia; Zhao, Lanbo; Wang, Lei; Zhang, Kailu; Yin, Panyue; Guo, Lin; Wei, Jing; Li, Qiling

doi:10.3389/fcimb.2020.572570

Cited by 4 publications

(5 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In GI cancers, the microbiota has been recognized to be related to chemotherapy, radiotherapy, and immunotherapy efficacy (7,8,12,13), indicating that the intestinal microbiota is a novel target to improve anti-tumor treatment (13). The presence of microbes within tumors and adjacent normal tissues may indicate disease progression and their potential roles in cancer pathogenesis (14)(15)(16). Understanding the alterations in the microbial community and abundance in GI organs thus aids in the study of GI cancer diagnosis and therapy.…”

Section: Introductionmentioning

confidence: 99%

Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The gut microbiota has been previously linked with tumorigenesis and gastrointestinal cancer progression; however, intra-tumor microbiota analysis has just emerged and deserves increasing attention. Based on the public databases of The Cancer Microbiome Atlas (TCMA) and The Cancer Genome Atlas (TCGA), this study identified the tissue/organ microbial signatures generated from 443 biosamples of four major gastrointestinal cancer types, including esophageal carcinoma (ESCA), which further includes esophageal adenocarcinoma (EAD) and esophageal squamous cell carcinoma (ESCC), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), and rectum adenocarcinoma (READ). According to partial least squares discrimination analysis (PLS-DA), the profile differences in microbial communities between the tumor and normal samples were not particularly noticeable across the four cancer cohorts, whereas paired comparison analyses revealed several specific differences in bacteria between tumor and normal samples in the EAD, STAD, and COAD samples. The taxa classified from the phylum to genus level revealed a trend of distinguishable microbial profiles between upper and lower gastrointestinal tumors. The Bacteroidetes/Firmicutes ratio in lower gastrointestinal tract tumors was nearly three times that in upper gastrointestinal tract tumors. We also determined the relative tissue/organ-prevalent microbes for each of the four cohorts at the order and genus levels. Microbe Alistipes, Blautia, Pasteurellales, and Porphyromonas compositions were correlated with the clinical characteristics of patients with gastrointestinal cancer, particularly colorectal cancer. Taken together, our findings indicate that microbial profiles shift across different gastrointestinal cancer types and that microbial colonization is highly site-specific. Composition of specific microbes can be indicative of cancer stage or disease progression. Overall, this study indicates that the microbial community and abundance in human tissues can be determined using publicly available data, and provides a new perspective for intra-tissue/organ microbiota research.

show abstract

Section: Introductionmentioning

confidence: 99%

Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Further, an Massachusetts Institute of Technology (MIT) team found that mice infected with citrobacter murine were also more likely to develop colon cancer 104 . In 2003, Susan Erdman's team at MIT showed that H. pylori caused colon cancer in immune‐compromised mice 105 .…”

Section: Human Carcinogenic or Cancer‐promoting Microbiomesmentioning

confidence: 99%

“…103 Further, an Massachusetts Institute of Technology (MIT) team found that mice infected with citrobacter murine were also more likely to develop colon cancer. 104 In 2003, Susan Erdman's team at MIT showed that H. pylori caused colon cancer in immune-compromised mice. 105 In 2006, Erdman's team infected a particular mouse model with H. hepaticus and continued to observe subsequent changes in the mice.…”

Section: Gut Microbiomes and Crcmentioning

confidence: 99%

Human microbiomes in cancer development and therapy

Xia

Liu

et al. 2023

MedComm

View full text Add to dashboard Cite

Colonies formed by bacteria, archaea, fungi, and viral groups and their genomes, metabolites, and expressed proteins constitute complex human microbiomes. An increasing evidences showed that carcinogenesis and disease progression were link to microbiomes. Different organ sources, their microbial species, and their metabolites are different; the mechanisms of carcinogenic or procancerous are also different. Here, we summarize how microbiomes contribute to carcinogenesis and disease progression in cancers of the skin, mouth, esophagus, lung, gastrointestinal, genital, blood, and lymph malignancy. We also insight into the molecular mechanisms of triggering, promoting, or inhibiting carcinogenesis and disease progress induced by microbiomes or/and their secretions of bioactive metabolites. And then, the strategies of application of microorganisms in cancer treatment were discussed in detail. However, the mechanisms by which human microbiomes function are still poorly understood. The bidirectional interactions between microbiotas and endocrine systems need to be clarified. Probiotics and prebiotics are believed to benefit human health via a variety of mechanisms, in particular, in tumor inhibition. It is largely unknown how microbial agents cause cancer or how cancer progresses. We expect this review may open new perspectives on possible therapeutic approaches of patients with cancer.

show abstract

“…Evidence from a plethora of studies indicates that pathogenic microbes are responsible for over 20% of cancer cases [ 82 , 83 ]. In some cases, the microbiota was shown to influence cancer development by modulating inflammation signals and inducing genomic instability of host cells [ 84 , 85 ].…”

Section: Role Of the Human Microbiome In Tumor Development And Progre...mentioning

confidence: 99%

“…They observed a high abundance of Lactobacillus and Gardnerella in the female, while Corynebacterium, Staphylococcus, and Streptococcus are the most abundant urinary microbiota in the male [81]. Microbiota is the term used to describe a collection of microorganisms-viruses, bacteria, archaea, fungi, bacteriophage, and protozoans-specific to a particular body site or Microbiota is the term used to describe a collection of microorganisms-viruses, bacteria, archaea, fungi, bacteriophage, and protozoans-specific to a particular body site or Evidence from a plethora of studies indicates that pathogenic microbes are responsible for over 20% of cancer cases [82,83]. In some cases, the microbiota was shown to influence cancer development by modulating inflammation signals and inducing genomic instability of host cells [84,85].…”

Section: Role Of the Human Microbiome In Tumor Development And Progre...mentioning

confidence: 99%

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer

Oseni

Naar

Pavlović

et al. 2023

Cancers

View full text Add to dashboard Cite

Chronic inflammation is now recognized as one of the major risk factors and molecular hallmarks of chronic prostatitis, benign prostatic hyperplasia (BPH), and prostate tumorigenesis. However, the molecular mechanisms by which chronic inflammation signaling contributes to the pathogenesis of these prostate diseases are poorly understood. Previous efforts to therapeutically target the upstream (e.g., TLRs and IL1-Rs) and downstream (e.g., NF-κB subunits and cytokines) inflammatory signaling molecules in people with these conditions have been clinically ambiguous and unsatisfactory, hence fostering the recent paradigm shift towards unraveling and understanding the functional roles and clinical significance of the novel and relatively underexplored inflammatory molecules and pathways that could become potential therapeutic targets in managing prostatic diseases. In this review article, we exclusively discuss the causal and molecular drivers of prostatitis, BPH, and prostate tumorigenesis, as well as the potential impacts of microbiome dysbiosis and chronic inflammation in promoting prostate pathologies. We specifically focus on the importance of some of the underexplored druggable inflammatory molecules, by discussing how their aberrant signaling could promote prostate cancer (PCa) stemness, neuroendocrine differentiation, castration resistance, metabolic reprogramming, and immunosuppression. The potential contribution of the IL1R-TLR-IRAK-NF-κBs signaling molecules and NLR/inflammasomes in prostate pathologies, as well as the prospective benefits of selectively targeting the midstream molecules in the various inflammatory cascades, are also discussed. Though this review concentrates more on PCa, we envision that the information could be applied to other prostate diseases. In conclusion, we have underlined the molecular mechanisms and signaling pathways that may need to be targeted and/or further investigated to better understand the association between chronic inflammation and prostate diseases.

show abstract

Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Cited by 4 publications

References 204 publications

Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer

Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer

Human microbiomes in cancer development and therapy

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer

Contact Info

Product

Resources

About